Shots:

• The first patient has been dosed in a P-lll trial that evaluated the efficacy and safety of KX-826 for treating 416 male AGA patients in China for 24wks. on Dec 31, 2021
• The P-III study will be carried out in 26 top dermatology medical institutions across China. The company is planning to complete the study in 2022 while the enrolment is anticipated to be completed by Jun 2022
• On Nov 24, 2021, Kintor Pharma reported that China's NMPA approved the protocol for the pivotal P-III study of KX-826 which is an AR antagonist and a potential first-in-class topical drug for AGA and acne vulgaris

Ref: PR Newswire | Image: AA Stocks